Cannabis Pharmacogenomics: A Path to Personalized Medicine

Overview

Journal Curr Issues Mol Biol

Publisher MDPI

Specialty Molecular Biology

Date 2023 May 15

PMID 37185752

Authors

Mariana Babayeva

Zvi G Loewy

Affiliations

Soon will be listed here.

Abstract

Cannabis and related compounds have created significant research interest as a promising therapy in many disorders. However, the individual therapeutic effects of cannabinoids and the incidence of side effects are still difficult to determine. Pharmacogenomics may provide the answers to many questions and concerns regarding the cannabis/cannabinoid treatment and help us to understand the variability in individual responses and associated risks. Pharmacogenomics research has made meaningful progress in identifying genetic variations that play a critical role in interpatient variability in response to cannabis. This review classifies the current knowledge of pharmacogenomics associated with medical marijuana and related compounds and can assist in improving the outcomes of cannabinoid therapy and to minimize the adverse effects of cannabis use. Specific examples of pharmacogenomics informing pharmacotherapy as a path to personalized medicine are discussed.

Citing Articles

Predicting therapy dropout in chronic pain management: a machine learning approach to cannabis treatment.

Visibelli A, Finetti R, Roncaglia B, Poli P, Spiga O, Santucci A Front Artif Intell. 2025; 8:1557894.

PMID: 40051572 PMC: 11882547. DOI: 10.3389/frai.2025.1557894.

Adverse events associated with the use of cannabis-based products in people living with cancer: a systematic scoping review.

Cheah I, Hunter J, Gelissen I, Chan W, Harnett J Support Care Cancer. 2024; 33(1):40.

PMID: 39694905 PMC: 11655613. DOI: 10.1007/s00520-024-09087-w.

The Evolving Role of Cannabidiol-Rich Cannabis in People with Autism Spectrum Disorder: A Systematic Review.

Jawed B, Esposito J, Pulcini R, Zakir S, Botteghi M, Gaudio F Int J Mol Sci. 2024; 25(22).

PMID: 39596518 PMC: 11595093. DOI: 10.3390/ijms252212453.

Non-linear plasma protein binding of cannabidiol.

Babayeva M, Srdanovic I J Cannabis Res. 2024; 6(1):27.

PMID: 38902820 PMC: 11191238. DOI: 10.1186/s42238-024-00238-8.

The Use of Compounds Derived from in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders.

Stasilowicz-Krzemien A, Nogalska W, Maszewska Z, Maleszka M, Dobron M, Szary A Int J Mol Sci. 2024; 25(11).

PMID: 38891938 PMC: 11171823. DOI: 10.3390/ijms25115749.

References

Zhang H, Yang Q, Zheng W, Ouyang Y, Yang M, Wang F . CYP gene family variants as potential protective factors in drug addiction in Han Chinese. J Gene Med. 2016; 18(8):147-53. DOI: 10.1002/jgm.2887. View

Spiro A, Wong A, Boucher A, Arnold J . Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice. PLoS One. 2012; 7(4):e35937. PMC: 3335007. DOI: 10.1371/journal.pone.0035937. View

Agrawal A, Pergadia M, Saccone S, Lynskey M, Wang J, Martin N . An autosomal linkage scan for cannabis use disorders in the nicotine addiction genetics project. Arch Gen Psychiatry. 2008; 65(6):713-21. DOI: 10.1001/archpsyc.65.6.713. View

Diekstra M, Belaustegui A, Swen J, Boven E, Castellano D, Gelderblom H . Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. Pharmacogenomics J. 2016; 17(1):42-46. DOI: 10.1038/tpj.2015.100. View

Hindocha C, Quattrone D, Freeman T, Murray R, Mondelli V, Breen G . Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry. 2020; 10(1):143. PMC: 7217850. DOI: 10.1038/s41398-020-0823-9. View

Diogenes A, Akopian A, Hargreaves K . NGF up-regulates TRPA1: implications for orofacial pain. J Dent Res. 2007; 86(6):550-5. DOI: 10.1177/154405910708600612. View

Badowski M . A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol. 2017; 80(3):441-449. PMC: 5573753. DOI: 10.1007/s00280-017-3387-5. View

Petrovic J, Pesic V, Lauschke V . Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet. 2019; 28(1):88-94. PMC: 6906321. DOI: 10.1038/s41431-019-0480-8. View

Gray R, Whalley B . The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020; 22(S1):10-15. DOI: 10.1684/epd.2020.1135. View

10.

Yang Z, Li L, Wang L, Yuan L, Xu M, Gu J . The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants. Acta Pharmacol Sin. 2017; 38(8):1184-1194. PMC: 5547550. DOI: 10.1038/aps.2016.157. View

11.

Hodges L, Markova S, Chinn L, Gow J, Kroetz D, Klein T . Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2010; 21(3):152-61. PMC: 3098758. DOI: 10.1097/FPC.0b013e3283385a1c. View

12.

Balliet R, Chen G, Dellinger R, Lazarus P . UDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility. Drug Metab Dispos. 2009; 38(3):484-90. PMC: 2835395. DOI: 10.1124/dmd.109.030569. View

13.

Iwai M, Maruo Y, Ito M, Yamamoto K, Sato H, Takeuchi Y . Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet. 2004; 49(3):123-128. DOI: 10.1007/s10038-003-0119-y. View

14.

Lopera V, Rodriguez A, Amariles P . Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review. J Clin Med. 2022; 11(5). PMC: 8911401. DOI: 10.3390/jcm11051154. View

15.

Agrawal A, Chou Y, Carey C, Baranger D, Zhang B, Sherva R . Genome-wide association study identifies a novel locus for cannabis dependence. Mol Psychiatry. 2017; 23(5):1293-1302. PMC: 5938138. DOI: 10.1038/mp.2017.200. View

16.

Isir A, Baransel C, Nacak M . An Information Theoretical Study of the Epistasis Between the CNR1 1359 G/A Polymorphism and the Taq1A and Taq1B DRD2 Polymorphisms: Assessing the Susceptibility to Cannabis Addiction in a Turkish Population. J Mol Neurosci. 2016; 58(4):456-60. DOI: 10.1007/s12031-016-0721-z. View

17.

Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V . Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther. 2006; 79(6):570-80. DOI: 10.1016/j.clpt.2006.02.003. View

18.

Gombert S, Rhein M, Winterpacht A, Munster T, Hillemacher T, Leffler A . Transient receptor potential ankyrin 1 promoter methylation and peripheral pain sensitivity in Crohn's disease. Clin Epigenetics. 2020; 12(1):1. PMC: 6938615. DOI: 10.1186/s13148-019-0796-9. View

19.

Naumov D, Kotova O, Gassan D, Sugaylo I, Afanaseva E, Sheludko E . Effect of and Polymorphisms on COPD Predisposition and Lung Function in COPD Patients. J Pers Med. 2021; 11(2). PMC: 7915134. DOI: 10.3390/jpm11020108. View

20.

Emamian E, Hall D, Birnbaum M, Karayiorgou M, Gogos J . Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004; 36(2):131-7. DOI: 10.1038/ng1296. View